Innate Pharma reports Full Year 2021 financial results and business update
First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers
Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line recurrent or metastatic head and neck cancer at ESMO Immuno-Oncology 2021 Congress
Monalizumab data from COAST trial presented at ESMO Congress 2021
Monalizumab and ANKET™ Data will be Presented at ESMO 2021 Virtual Congress
Innate Pharma reports Full Year 2020 financial results and business update
Innate Pharma advances lacutamab clinical development program
Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas
Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
Innate Pharma receives PRIME designation from the European Medicines Agency for lacutamab in Sézary syndrome
